|  | Conditions & Treatments | Cholesterol

Total Cholesterol 250 mg/dL: Interpretation, Risks, and Action Plan

A total cholesterol level of 250 mg/dL is classified as borderline high (200–239 mg/dL is borderline; ≥240 mg/dL is high). This value signals an increased risk for atherosclerotic cardiovascular disease (ASCVD), including heart attack and stroke.

What This Number Means

  • Total cholesterol includes LDL ("bad"), HDL ("good"), and VLDL (triglyceride-rich) fractions.
  • A level of 250 mg/dL often reflects elevated LDL cholesterol, but a full lipid panel (LDL, HDL, triglycerides) is needed for accurate risk stratification.
  • Guidelines (ACC/AHA) recommend LDL < 100 mg/dL for primary prevention; < 70 mg/dL for high-risk patients.

Key Contributing Factors

  • Diet high in saturated/trans fats, refined carbohydrates, added sugars
  • Physical inactivity
  • Overweight/obesity (especially central adiposity)
  • Smoking
  • Insulin resistance, type 2 diabetes, metabolic syndrome
  • Hypertension
  • Family history of premature ASCVD or familial hypercholesterolemia
  • Certain medications (e.g., beta-blockers, thiazides, protease inhibitors)
  • Hypothyroidism, nephrotic syndrome, liver disease

Lifestyle Interventions (First-Line)

  • Adopt a Mediterranean-style or DASH diet: emphasize vegetables, fruits, whole grains, legumes, nuts, fatty fish, olive oil; limit red meat, full-fat dairy, processed foods.
  • Increase soluble fiber to 10–25 g/day (oats, barley, beans, psyllium).
  • Add plant sterols/stanols 2 g/day (fortified foods or supplements).
  • Exercise: ≥150 min/week moderate-intensity aerobic + 2 days resistance training.
  • Weight loss: 5–10% body weight reduction significantly improves lipids.
  • Quit smoking – improves HDL and endothelial function.
  • Limit alcohol to ≤1 drink/day (women), ≤2 (men).

Pharmacologic Therapy

Indicated based on 10-year ASCVD risk (Pooled Cohort Equations), LDL level, and comorbidities:

  • Statins (atorvastatin, rosuvastatin) – first-line; reduce LDL 30–55%.
  • Ezetimibe – add-on; blocks intestinal cholesterol absorption (~15–20% additional LDL lowering).
  • PCSK9 inhibitors (alirocumab, evolocumab) – for very high-risk patients not at goal on maximally tolerated statin.
  • Bempedoic acid – alternative for statin-intolerant patients.
  • Older agents (bile acid sequestrants, niacin, fibrates) now reserved for specific indications.

Next Steps

  1. Obtain a fasting lipid panel with LDL, HDL, triglycerides.
  2. Calculate 10-year ASCVD risk with your clinician.
  3. Discuss personalized targets and whether medication is warranted.
  4. Recheck lipids in 4–12 weeks after initiating lifestyle or drug therapy.

Do not ignore this result. Early intervention prevents plaque progression and cardiovascular events.

Cholesterol - Related Articles